Joe Cabral, Principal, Frazier Life Sciences
Joe Cabral is a Principal on the Frazier Life Sciences investment team, where he focuses on evaluating private investment opportunities and forming new companies. He co-led FLS’ investments in and currently serves on the Boards of Halda Therapeutics and three other private companies still in stealth mode. He is currently a Board Observer at Alpha-9 Oncology, Hillstar Bio and Lassen Therapeutics. Since he joined the firm in 2021 he has contributed to multiple other investments, including NewAmsterdam Pharma (NASDAQ: NAMS) via his role as VP, Acquisitions for Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC).
Prior to joining FLS, Joe was in venture creation at Flagship Pioneering and was part of the founding team at Generate:Biomedicines, where he held operational roles in protein engineering and strategy. Previously, Joe was an early employee at Moderna working in molecular biology and informatics, where he led research activities in modified RNA biophysics and protein translation, and, helped launch mRNA-4157, a personalized cancer vaccine program.
Joe received his MBA from the Ross School of Business at the University of Michigan, where he received multiple awards recognizing his outstanding performance in entrepreneurship and venture capital. Joe also holds an M.S. in Genomics and B.S. in Biology from the University of Connecticut.
